LONDON-- GlaxoSmithKline PLC (GSK.LN) Wednesday said a Phase III study of its shingles vaccine Shingrix showed a strong immune response in older adults, meeting its primary objective.

Shares at 1309GMT, down 13 pence, or 0.8%, at 1,680 pence valuing the company at GBP82.62 billion

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

June 21, 2017 09:25 ET (13:25 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.